136 related articles for article (PubMed ID: 12590235)
1. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.
Rulyak SJ; Saunders MD; Lee SD
J Clin Gastroenterol; 2003 Mar; 36(3):234-7. PubMed ID: 12590235
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
[TBL] [Abstract][Full Text] [Related]
3. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
Almer SH; Hjortswang H; Hindorf U
Dig Liver Dis; 2009 Mar; 41(3):194-200. PubMed ID: 18799369
[TBL] [Abstract][Full Text] [Related]
4. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.
Gisbert JP; González-Lama Y; Maté J
Am J Gastroenterol; 2007 Jul; 102(7):1518-27. PubMed ID: 17391318
[TBL] [Abstract][Full Text] [Related]
5. Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease.
Kane S; Cohen SM; Hart J
Inflamm Bowel Dis; 2004 Sep; 10(5):652-4. PubMed ID: 15472529
[TBL] [Abstract][Full Text] [Related]
6. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Bonaz B; Boitard J; Marteau P; Lémann M; Coffin B; Flourié B; Belaiche J; Cadiot G; Metman EH; Cortot A; Colombel JF;
Aliment Pharmacol Ther; 2003 Aug; 18(4):401-8. PubMed ID: 12940925
[TBL] [Abstract][Full Text] [Related]
7. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.
Dubinsky MC; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
Inflamm Bowel Dis; 2001 Aug; 7(3):181-9. PubMed ID: 11515842
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
Taylor KM; Ward MG; Blaker PA; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
[TBL] [Abstract][Full Text] [Related]
9. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
Musumba CO
Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
[TBL] [Abstract][Full Text] [Related]
10. Further experience with the use of 6-thioguanine in patients with Crohn's disease.
Ansari A; Elliott T; Fong F; Arenas-Hernandez M; Rottenberg G; Portmann B; Lucas S; Marinaki A; Sanderson J
Inflamm Bowel Dis; 2008 Oct; 14(10):1399-405. PubMed ID: 18521912
[TBL] [Abstract][Full Text] [Related]
11. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
de Boer NK; Reinisch W; Teml A; van Bodegraven AA; Schwab M; Lukas M; Ochsenkühn T; Petritsch W; Knoflach P; Almer S; van der Merwe SW; Herrlinger KR; Seiderer J; Vogelsang H; Mulder CJ;
Digestion; 2006; 73(1):25-31. PubMed ID: 16493198
[TBL] [Abstract][Full Text] [Related]
12. 6-MP metabolite levels: a potential guide to Crohn's disease therapy.
Sandborn WJ
Gastroenterology; 1997 Aug; 113(2):690-2. PubMed ID: 9247497
[No Abstract] [Full Text] [Related]
13. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine.
de Jong D; Mulder CJ; van Sorge AA
Gut; 2001 Dec; 49(6):874. PubMed ID: 11758505
[No Abstract] [Full Text] [Related]
14. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
15. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
16. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
17. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
Gupta P; Gokhale R; Kirschner BS
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):450-4. PubMed ID: 11698762
[TBL] [Abstract][Full Text] [Related]
18. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
Pavlidis P; Ansari A; Duley J; Oancea I; Florin T
Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
[TBL] [Abstract][Full Text] [Related]
19. Remission maintenance by tioguanine in chronic active Crohn's disease.
Herrlinger KR; Deibert P; Schwab M; Kreisel W; Fischer C; Fellermann K; Stange EF
Aliment Pharmacol Ther; 2003 Jun; 17(12):1459-64. PubMed ID: 12823147
[TBL] [Abstract][Full Text] [Related]
20. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis.
Teml A; Schwab M; Harrer M; Miehsler W; Schaeffeler E; Dejaco C; Mantl M; Schneider B; Vogelsang H; Reinisch W
Scand J Gastroenterol; 2005 Oct; 40(10):1205-13. PubMed ID: 16265777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
